COMPARISON OF PARATHYROIDECTOMIES WITH PARICALCITOL OR CINACALCET FOR TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN HEMODIALYSIS PATIENTS

被引：0
|
作者：
Walton, Surrey M. [1 ]
Schumock, Glen T. [1 ]
Lee, Todd A. [1 ]
Marx, Steven E. [2 ]
Audhya, Paul [2 ]
Andress, Dennis L. [2 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2009年 / 53卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
222
引用
收藏
页码：A78 / A78
页数：1
相关论文
共 50 条
  • [21] Is cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?
    Arenas, M. D.
    Rebollo, P.
    Alvarez-Ude, F.
    Prieto, L.
    Gil, M. T.
    Malek, T.
    Moledous, A.
    Nunez, C.
    NEFROLOGIA, 2008, 28 (05): : 511 - 516
  • [22] Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism
    Kuczera, Piotr
    Adamczak, Marcin
    Machnik, Grzegorz
    Okopien, Boguslaw
    Wiecek, Andrzej
    NEPHRON, 2018, 139 (04) : 286 - 292
  • [23] Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
    Kuczera, Piotr
    Adamczak, Marcin
    Wiecek, Andrzej
    BMC NEPHROLOGY, 2016, 17 : 1 - 7
  • [24] Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients
    Owda, AK
    Alam, MG
    Kumar, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02): : 188 - 188
  • [25] Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
    Piotr Kuczera
    Marcin Adamczak
    Andrzej Więcek
    BMC Nephrology, 17
  • [26] Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
    Xiu Chen
    Feng Zhao
    Wei-Juan Pan
    Jia-Mei Di
    Wei-Nan Xie
    Ling Yuan
    Zhi Liu
    World Journal of Clinical Cases, 2021, (33) : 10172 - 10179
  • [27] Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
    Chen, Xiu
    Zhao, Feng
    Pan, Wei-Juan
    Di, Jia-Mei
    Xie, Wei-Nan
    Yuan, Ling
    Liu, Zhi
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (33) : 10172 - 10179
  • [28] Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol
    Afsar, Baris
    Agca, Erhan
    Turk, Suleyman
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (11): : 1280 - 1285
  • [29] Effect of paricalcitol on biochemical markers of secondary hyperparathyroidism in hemodialysis patients
    Zdravkovic, J.
    Georgijev, D. Ristic
    Zdravkovic, A.
    Zdravkovic, K.
    Popovic, M.
    Stojanovic, S.
    CLINICA CHIMICA ACTA, 2024, 558
  • [30] Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
    Ni, Zhaohui
    Liang, Xinling
    Wu, Chia-Chao
    Jin, Kyubok
    Kim, Yong-Lim
    Lu, Kuo-Cheng
    Chan, Tak Mao
    Fukagawa, Masafumi
    Kinoshita, Jun
    Nagai, Chisato
    Kojima, Masahiro
    Yu, Xueqing
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (11): : 2294 - 2306
12345